+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07720271

Evaluating the Safety and Effectiveness of Once-Daily Oral Zenagamtide for Adults with Obesity and Overweight

Led by Novo Nordisk A/S · Updated on 2026-09-28

950

Participants Needed

41

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating zenagamtide, an oral medication, to determine its safety and effectiveness in helping adults with excess body weight lose weight. This phase 3 clinical trial compares zenagamtide against a placebo to understand its impact as part of a treatment for overweight and obesity. The study involves participants aged 18 and older who will be randomly assigned to different treatment groups. Participants will receive either one of five dose levels of zenagamtide or a placebo, both taken orally once daily. These treatments are combined with a reduced-calorie diet and increased physical activity to support weight loss efforts. The study treatment period lasts up to 76 weeks, during which participants follow the lifestyle changes alongside the medication or placebo. Throughout the study, participants will be monitored regularly to assess changes in body weight as the primary outcome, alongside secondary measures like waist circumference and systolic blood pressure. Safety and adherence will also be tracked. The total participation duration extends up to about 76 weeks, with ongoing evaluations to understand the treatment effects over this timeframe.

CONDITIONS

Brief Title

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Research Team

N

Novo Nordisk

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here